- Home
- API vs ALLO Comparison
API vs ALLO Comparison
Compare API & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- ALLO
- Stock Information
- Founded
- API 2013
- ALLO 2017
- Country
- API United States
- ALLO United States
- Employees
- API N/A
- ALLO N/A
- Industry
- API Computer Software: Prepackaged Software
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- API Technology
- ALLO Health Care
- Exchange
- API Nasdaq
- ALLO Nasdaq
- Market Cap
- API 315.7M
- ALLO 252.9M
- IPO Year
- API 2020
- ALLO 2018
- Fundamental
- Price
- API $3.62
- ALLO $1.21
- Analyst Decision
- API Strong Buy
- ALLO Buy
- Analyst Count
- API 1
- ALLO 12
- Target Price
- API $6.00
- ALLO $8.80
- AVG Volume (30 Days)
- API 358.3K
- ALLO 3.1M
- Earning Date
- API 11-24-2025
- ALLO 11-13-2025
- Dividend Yield
- API N/A
- ALLO N/A
- EPS Growth
- API N/A
- ALLO N/A
- EPS
- API N/A
- ALLO N/A
- Revenue
- API $133,554,000.00
- ALLO N/A
- Revenue This Year
- API $7.20
- ALLO N/A
- Revenue Next Year
- API $11.26
- ALLO $100.00
- P/E Ratio
- API N/A
- ALLO N/A
- Revenue Growth
- API N/A
- ALLO N/A
- 52 Week Low
- API $2.53
- ALLO $0.86
- 52 Week High
- API $6.99
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- API 47.08
- ALLO 45.93
- Support Level
- API $3.49
- ALLO $1.21
- Resistance Level
- API $3.64
- ALLO $1.33
- Average True Range (ATR)
- API 0.17
- ALLO 0.10
- MACD
- API -0.01
- ALLO -0.02
- Stochastic Oscillator
- API 26.61
- ALLO 4.41
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.